Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$87 Mln
P/E Ratio
--
P/B Ratio
4.85
Industry P/E
--
Debt to Equity
0
ROE
-0.63 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-41.02 Mln
EBITDA
$-86.12 Mln
Net Profit
$-93.38 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
| 17.67 | -13.61 | -8.24 | -9.30 | 0.87 | 7.24 | -2.93 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
| -39.95 | -8.71 | 43.10 | -3.26 | -6.40 | -16.75 | 66.48 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.69 | 4.48 | -- | -- | |
| 8.02 | 109.51 | 17.6 | -- |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of... chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Address: 3150 Almaden Expressway, San Jose, CA, United States, 95118 Read more
CEO, Chairman & Co-Chair of CBAB
Dr. Amit Kumar Ph.D.
CEO, Chairman & Co-Chair of CBAB
Dr. Amit Kumar Ph.D.
Headquarters
San Jose, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Anixa Biosciences Inc (ANIX) stood at $ 21 Mln as on 31-Jan-25
The share price of Anixa Biosciences Inc (ANIX) is $2.73 (NASDAQ) as of 23-Apr-2025 13:37 EDT. Anixa Biosciences Inc (ANIX) has given a return of 0.87% in the last 3 years.
Anixa Biosciences Inc (ANIX) has a market capitalisation of $ 87 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Anixa Biosciences Inc (ANIX) is 4.85 times as on 22-Apr-2025, a 120% premium to its peers’ median range of 2.20 times.
Since, TTM earnings of Anixa Biosciences Inc (ANIX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Anixa Biosciences Inc (ANIX) and enter the required number of quantities and click on buy to purchase the shares of Anixa Biosciences Inc (ANIX).
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Address: 3150 Almaden Expressway, San Jose, CA, United States, 95118
The CEO & director of Dr. Amit Kumar Ph.D.. is Anixa Biosciences Inc (ANIX), and CFO & Sr. VP is Dr. Amit Kumar Ph.D..
There is no promoter pledging in Anixa Biosciences Inc (ANIX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
11
|
|
|
0
|
|
|
11
|
|
|
0
|
| Anixa Biosciences Inc. (ANIX) | Ratios |
|---|---|
|
Return on equity(%)
|
-62.31
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Anixa Biosciences Inc (ANIX) was $0 Mln.
$0.01
(
